안트로젠

065660KOSDAQ기타 전문 도매업

48.0 / 100

Reference Date: 2026-04-13

Financial Score17.0 / 40

News Sentiment15.0 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 33.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Antrogen is a biotech company specializing in the development and production of stem cell-based therapeutics, having commercialized the world's first adipose-derived stem cell treatment for Crohn's disease fistulas, 'Cupistem,' in 2012. It also holds exclusive distribution rights for pulmonary hypertension treatments 'Remodulin' and 'Tyvaso' in South Korea, while expanding its pipeline for tissue-engineered therapies and treatments for rare/incurable diseases.

Number of Employees

32people

Average Salary

34.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.634.0Point

PBR

4.38Industry Average 0.630.0Point

7.0x industry avg (risky)

ROE

-1.39Industry Average 2.090.0Point

Well below industry avg

Debt Ratio

0.22Industry Average 7.878.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲30.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 0Negative 0Average Sentiment Score 80

Positive
"피부재생 줄기세포 치료제 日서 첫 허가"
안트로젠의 피부 유전질환 줄기세포 치료제 '알로스템'이 일본에서 정식 품목 허가를 받아 토종 줄기세포 치료제로는 첫 사례가 되었다.

Detailed Momentum

52-week position5.0Point

52w mid range (48%)

Current 38,300Won52-week high 58,00052-week low 19,530

1-month return0.0Point

1m -33.16% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral정기주주총회결과2026-03-20
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-20